Posted by Michael Wonder on 29 Aug 2020
Rybelsus is included in the high-cost protection with restriction
28 August 2020 - Rybelsus (semaglutide) is intended for the treatment of adults with type 2 diabetes in adults as the only drug for type 2 diabetes when treatment with metformin hydrochloride is inappropriate, or in combination with other drugs for type 2 diabetes mellitus.
Rybelsus is included in the high-cost protection with limited subsidy since 28 August 2020.
The restriction means that Rybelsus is only subsidised when the patient has first tried treatment with metformin, a sulphonylurea or insulin, or when these are not suitable.
